Pfizer-Allergan's Tie-Up Isn't the Only Inversion in Town

Is Pfizer-Allergan the End of Tax Inversion Deals?

The U.S. Treasury’s new rules to prevent companies from buying overseas businesses to reduce taxes have spelled the end of the biggest deal announced in 2015. While the demise of Pfizer Inc. and Allergan Plc’s $160 billion merger might be the most dramatic result, it isn’t the only transaction that could be affected.

Below is a list of companies who are working on corporate inversion deals or who have carried out inversions in the past. The proposed rules target serial inversions and won't necessarily affect these transactions.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.